HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens
Abstract Background Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin's lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been repor...
Gespeichert in:
| Veröffentlicht in: | Digestive and liver disease 2011-02, Vol.43 (2), p.139-142 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 142 |
|---|---|
| container_issue | 2 |
| container_start_page | 139 |
| container_title | Digestive and liver disease |
| container_volume | 43 |
| creator | Marignani, Massimo Mangone, Manuela Cox, M. Christina Angeletti, Stefano Veggia, Barbara Ferrari, Antonella di Fonzo, Michela Begini, Paola Gigante, Elia Laverde, Giacinto Aloe-Spiriti, Antonietta Monarca, Bruno Fave, Gianfranco Delle |
| description | Abstract Background Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin's lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with rituximab-containing regimens. Aim to evaluate the liver-related effects of rituximab-containing regimens on HCV-positive CD20-positive B-cell NHL patients. Patients and methods Retrospective analysis of 104 consecutive patients. HCV status was determined, and development of hepatitis flares analysed. Results Nine patients (8.6%) were HCV-positive. No correlation was shown between viral load and alanine transaminase levels. Three of the 9 HCV-positive, and none of the 95 HCV-negative developed hepatitis flares ( p < 0.001). At the 12-month follow-up hepatitis flare patients were alive and in remission for their haematological disease and no hepatitis flares, liver-related death had developed. Conclusions HCV-positive status may represent a risk factor for the development of hepatic flares in B-cell NHL patients receiving rituximab-containing regimens. Despite the increase in liver function tests, there were no major clinical events. |
| doi_str_mv | 10.1016/j.dld.2010.05.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_845391756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S159086581000174X</els_id><sourcerecordid>845391756</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-62d1a3ca085ff3c40f58b7b9d9baaed531128399ce435a517db9bb00553b3d973</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEoqXwAbgg33rK1o7jxBESEl1BF6kSB_6Im-XYk11vE3vxOIW98slxtIUDB05jj957mvlNUbxkdMUoa672KzvaVUXzn4pVLo-KcyZbWXLRVI_zW3S0lI2QZ8UzxD2lFWsEfVqcVVSIupbyvPi1WX8tDwFdcvdAMOk0I9Hekh0cdMpdJMOoIyBxniwd8AnJD5d25Lo0MI7EB19ugt3eOX-JZDxOh12YNEkRdAJ7kkaX5p9u0n1pgk_aeee3JMLWTeDxefFk0CPCi4d6UXx5_-7zelPefrz5sH57W5qatqlsKss0N5pKMQw89wYh-7bvbNdrDVZwxirJu85AzYUWrLV91_c0b8p7bruWXxSXp9xDDN9nwKQmh8sK2kOYUcla8I61oslKdlKaGBAjDOoQ8_TxqBhVC3m1V5m8WsgrKlQu2fPqIX3uJ7B_HX9QZ8HrkwDyjvcOokKTaRqwLoJJygb33_g3_7jNmDEaPd7BEXAf5ugzPMUUVoqqT8vpl8szSilr62_8N6B7qxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>845391756</pqid></control><display><type>article</type><title>HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Marignani, Massimo ; Mangone, Manuela ; Cox, M. Christina ; Angeletti, Stefano ; Veggia, Barbara ; Ferrari, Antonella ; di Fonzo, Michela ; Begini, Paola ; Gigante, Elia ; Laverde, Giacinto ; Aloe-Spiriti, Antonietta ; Monarca, Bruno ; Fave, Gianfranco Delle</creator><creatorcontrib>Marignani, Massimo ; Mangone, Manuela ; Cox, M. Christina ; Angeletti, Stefano ; Veggia, Barbara ; Ferrari, Antonella ; di Fonzo, Michela ; Begini, Paola ; Gigante, Elia ; Laverde, Giacinto ; Aloe-Spiriti, Antonietta ; Monarca, Bruno ; Fave, Gianfranco Delle</creatorcontrib><description>Abstract Background Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin's lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with rituximab-containing regimens. Aim to evaluate the liver-related effects of rituximab-containing regimens on HCV-positive CD20-positive B-cell NHL patients. Patients and methods Retrospective analysis of 104 consecutive patients. HCV status was determined, and development of hepatitis flares analysed. Results Nine patients (8.6%) were HCV-positive. No correlation was shown between viral load and alanine transaminase levels. Three of the 9 HCV-positive, and none of the 95 HCV-negative developed hepatitis flares ( p < 0.001). At the 12-month follow-up hepatitis flare patients were alive and in remission for their haematological disease and no hepatitis flares, liver-related death had developed. Conclusions HCV-positive status may represent a risk factor for the development of hepatic flares in B-cell NHL patients receiving rituximab-containing regimens. Despite the increase in liver function tests, there were no major clinical events.</description><identifier>ISSN: 1590-8658</identifier><identifier>EISSN: 1878-3562</identifier><identifier>DOI: 10.1016/j.dld.2010.05.010</identifier><identifier>PMID: 20554488</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived - administration & dosage ; Antibodies, Monoclonal, Murine-Derived - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B-cell non-Hodgkin's lymphoma ; Chemotherapy ; Disease Progression ; Female ; Follow-Up Studies ; Gastroenterology and Hepatology ; Hepacivirus - isolation & purification ; Hepatitis - etiology ; Hepatitis C - complications ; Hepatitis C virus ; Humans ; Lymphoma, B-Cell - complications ; Lymphoma, B-Cell - drug therapy ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; Rituximab ; Treatment Outcome</subject><ispartof>Digestive and liver disease, 2011-02, Vol.43 (2), p.139-142</ispartof><rights>Editrice Gastroenterologica Italiana S.r.l.</rights><rights>2010 Editrice Gastroenterologica Italiana S.r.l.</rights><rights>Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-62d1a3ca085ff3c40f58b7b9d9baaed531128399ce435a517db9bb00553b3d973</citedby><cites>FETCH-LOGICAL-c407t-62d1a3ca085ff3c40f58b7b9d9baaed531128399ce435a517db9bb00553b3d973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.dld.2010.05.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20554488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marignani, Massimo</creatorcontrib><creatorcontrib>Mangone, Manuela</creatorcontrib><creatorcontrib>Cox, M. Christina</creatorcontrib><creatorcontrib>Angeletti, Stefano</creatorcontrib><creatorcontrib>Veggia, Barbara</creatorcontrib><creatorcontrib>Ferrari, Antonella</creatorcontrib><creatorcontrib>di Fonzo, Michela</creatorcontrib><creatorcontrib>Begini, Paola</creatorcontrib><creatorcontrib>Gigante, Elia</creatorcontrib><creatorcontrib>Laverde, Giacinto</creatorcontrib><creatorcontrib>Aloe-Spiriti, Antonietta</creatorcontrib><creatorcontrib>Monarca, Bruno</creatorcontrib><creatorcontrib>Fave, Gianfranco Delle</creatorcontrib><title>HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens</title><title>Digestive and liver disease</title><addtitle>Dig Liver Dis</addtitle><description>Abstract Background Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin's lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with rituximab-containing regimens. Aim to evaluate the liver-related effects of rituximab-containing regimens on HCV-positive CD20-positive B-cell NHL patients. Patients and methods Retrospective analysis of 104 consecutive patients. HCV status was determined, and development of hepatitis flares analysed. Results Nine patients (8.6%) were HCV-positive. No correlation was shown between viral load and alanine transaminase levels. Three of the 9 HCV-positive, and none of the 95 HCV-negative developed hepatitis flares ( p < 0.001). At the 12-month follow-up hepatitis flare patients were alive and in remission for their haematological disease and no hepatitis flares, liver-related death had developed. Conclusions HCV-positive status may represent a risk factor for the development of hepatic flares in B-cell NHL patients receiving rituximab-containing regimens. Despite the increase in liver function tests, there were no major clinical events.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal, Murine-Derived - administration & dosage</subject><subject>Antibodies, Monoclonal, Murine-Derived - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B-cell non-Hodgkin's lymphoma</subject><subject>Chemotherapy</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology and Hepatology</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis - etiology</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C virus</subject><subject>Humans</subject><subject>Lymphoma, B-Cell - complications</subject><subject>Lymphoma, B-Cell - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Rituximab</subject><subject>Treatment Outcome</subject><issn>1590-8658</issn><issn>1878-3562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxSMEoqXwAbgg33rK1o7jxBESEl1BF6kSB_6Im-XYk11vE3vxOIW98slxtIUDB05jj957mvlNUbxkdMUoa672KzvaVUXzn4pVLo-KcyZbWXLRVI_zW3S0lI2QZ8UzxD2lFWsEfVqcVVSIupbyvPi1WX8tDwFdcvdAMOk0I9Hekh0cdMpdJMOoIyBxniwd8AnJD5d25Lo0MI7EB19ugt3eOX-JZDxOh12YNEkRdAJ7kkaX5p9u0n1pgk_aeee3JMLWTeDxefFk0CPCi4d6UXx5_-7zelPefrz5sH57W5qatqlsKss0N5pKMQw89wYh-7bvbNdrDVZwxirJu85AzYUWrLV91_c0b8p7bruWXxSXp9xDDN9nwKQmh8sK2kOYUcla8I61oslKdlKaGBAjDOoQ8_TxqBhVC3m1V5m8WsgrKlQu2fPqIX3uJ7B_HX9QZ8HrkwDyjvcOokKTaRqwLoJJygb33_g3_7jNmDEaPd7BEXAf5ugzPMUUVoqqT8vpl8szSilr62_8N6B7qxQ</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Marignani, Massimo</creator><creator>Mangone, Manuela</creator><creator>Cox, M. Christina</creator><creator>Angeletti, Stefano</creator><creator>Veggia, Barbara</creator><creator>Ferrari, Antonella</creator><creator>di Fonzo, Michela</creator><creator>Begini, Paola</creator><creator>Gigante, Elia</creator><creator>Laverde, Giacinto</creator><creator>Aloe-Spiriti, Antonietta</creator><creator>Monarca, Bruno</creator><creator>Fave, Gianfranco Delle</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens</title><author>Marignani, Massimo ; Mangone, Manuela ; Cox, M. Christina ; Angeletti, Stefano ; Veggia, Barbara ; Ferrari, Antonella ; di Fonzo, Michela ; Begini, Paola ; Gigante, Elia ; Laverde, Giacinto ; Aloe-Spiriti, Antonietta ; Monarca, Bruno ; Fave, Gianfranco Delle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-62d1a3ca085ff3c40f58b7b9d9baaed531128399ce435a517db9bb00553b3d973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal, Murine-Derived - administration & dosage</topic><topic>Antibodies, Monoclonal, Murine-Derived - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B-cell non-Hodgkin's lymphoma</topic><topic>Chemotherapy</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology and Hepatology</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis - etiology</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C virus</topic><topic>Humans</topic><topic>Lymphoma, B-Cell - complications</topic><topic>Lymphoma, B-Cell - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Rituximab</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marignani, Massimo</creatorcontrib><creatorcontrib>Mangone, Manuela</creatorcontrib><creatorcontrib>Cox, M. Christina</creatorcontrib><creatorcontrib>Angeletti, Stefano</creatorcontrib><creatorcontrib>Veggia, Barbara</creatorcontrib><creatorcontrib>Ferrari, Antonella</creatorcontrib><creatorcontrib>di Fonzo, Michela</creatorcontrib><creatorcontrib>Begini, Paola</creatorcontrib><creatorcontrib>Gigante, Elia</creatorcontrib><creatorcontrib>Laverde, Giacinto</creatorcontrib><creatorcontrib>Aloe-Spiriti, Antonietta</creatorcontrib><creatorcontrib>Monarca, Bruno</creatorcontrib><creatorcontrib>Fave, Gianfranco Delle</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive and liver disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marignani, Massimo</au><au>Mangone, Manuela</au><au>Cox, M. Christina</au><au>Angeletti, Stefano</au><au>Veggia, Barbara</au><au>Ferrari, Antonella</au><au>di Fonzo, Michela</au><au>Begini, Paola</au><au>Gigante, Elia</au><au>Laverde, Giacinto</au><au>Aloe-Spiriti, Antonietta</au><au>Monarca, Bruno</au><au>Fave, Gianfranco Delle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens</atitle><jtitle>Digestive and liver disease</jtitle><addtitle>Dig Liver Dis</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>43</volume><issue>2</issue><spage>139</spage><epage>142</epage><pages>139-142</pages><issn>1590-8658</issn><eissn>1878-3562</eissn><abstract>Abstract Background Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin's lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with rituximab-containing regimens. Aim to evaluate the liver-related effects of rituximab-containing regimens on HCV-positive CD20-positive B-cell NHL patients. Patients and methods Retrospective analysis of 104 consecutive patients. HCV status was determined, and development of hepatitis flares analysed. Results Nine patients (8.6%) were HCV-positive. No correlation was shown between viral load and alanine transaminase levels. Three of the 9 HCV-positive, and none of the 95 HCV-negative developed hepatitis flares ( p < 0.001). At the 12-month follow-up hepatitis flare patients were alive and in remission for their haematological disease and no hepatitis flares, liver-related death had developed. Conclusions HCV-positive status may represent a risk factor for the development of hepatic flares in B-cell NHL patients receiving rituximab-containing regimens. Despite the increase in liver function tests, there were no major clinical events.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>20554488</pmid><doi>10.1016/j.dld.2010.05.010</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-8658 |
| ispartof | Digestive and liver disease, 2011-02, Vol.43 (2), p.139-142 |
| issn | 1590-8658 1878-3562 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_845391756 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Antibodies, Monoclonal, Murine-Derived - administration & dosage Antibodies, Monoclonal, Murine-Derived - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-cell non-Hodgkin's lymphoma Chemotherapy Disease Progression Female Follow-Up Studies Gastroenterology and Hepatology Hepacivirus - isolation & purification Hepatitis - etiology Hepatitis C - complications Hepatitis C virus Humans Lymphoma, B-Cell - complications Lymphoma, B-Cell - drug therapy Male Middle Aged Retrospective Studies Risk Factors Rituximab Treatment Outcome |
| title | HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T18%3A57%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HCV-positive%20status%20and%20hepatitis%20flares%20in%20patients%20with%20B-cell%20non-Hodgkin's%20lymphoma%20treated%20with%20rituximab-containing%20regimens&rft.jtitle=Digestive%20and%20liver%20disease&rft.au=Marignani,%20Massimo&rft.date=2011-02-01&rft.volume=43&rft.issue=2&rft.spage=139&rft.epage=142&rft.pages=139-142&rft.issn=1590-8658&rft.eissn=1878-3562&rft_id=info:doi/10.1016/j.dld.2010.05.010&rft_dat=%3Cproquest_cross%3E845391756%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=845391756&rft_id=info:pmid/20554488&rft_els_id=1_s2_0_S159086581000174X&rfr_iscdi=true |